• Age ≥18 years, regardless of gender;

• Histologically or cytologically confirmed advanced/metastatic solid tumors (tumors with positive CD70 expression, confirmed histopathological ly with IHC 3+ score);

• Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemotherapy, radiotherapy, or targeted therapy);

• At least one measurable lesion per RECIST 1.1 criteria, with measurable lesions defined as:

∙ Extranodal lesions with a long axis ≥10mm on CT scan;

‣ Lymph node lesions with a short axis ≥15mm on CT scan;

‣ CT slice thickness ≤5mm.

• ECOG performance status of 0-2 ;

• Expected survival ≥12 weeks;

• No history of severe psychiatric disorders;

• Adequate organ function as defined by the following:

∙ Hematology: White blood cell count \>2.0×10⁹/L, neutrophils \>0.8×10⁹/L, lymphocytes \>0.5×10⁹/L, platelets \>50×10⁹/L, hemoglobin \>90g/L;

‣ Cardiac: Echocardiogram showing left ventricular ejection fraction (LVEF) ≥50%, and ECG with no significant abnormalities;

‣ Renal: Serum creatinine ≤2.0×ULN;

‣ Hepatic: ALT and AST ≤3.0×ULN (may be relaxed to ≤5.0×ULN in cases with liver tumor infiltration); total bilirubin ≤2.0×ULN (may be relaxed to ≤3.0×ULN in cases with Gilbert's syndrome or liver tumor infiltration);

‣ Oxygen saturation ≥92% without supplemental oxygen;

• Ability to undergo single or venous blood collection, with no contraindications to cellular collection;

⁃ Female subjects must agree to use reliable contraception (excluding fertility awareness methods) from the time of informed consent until 1 year after CAR-T cell infusion;

⁃ Subject or authorized guardian agrees to participate in the trial and signs the informed consent form (ICF), indicating understanding of the trial's purpose and procedures and willingness to participate.